Triple
T9632093
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | BioNTech |
E232831
|
entity |
| Predicate | developed |
P73
|
FINISHED |
| Object |
BNT162b2
BNT162b2 is an mRNA-based COVID-19 vaccine, co-developed by BioNTech and Pfizer, that became one of the first widely authorized vaccines against SARS-CoV-2.
|
E812198
|
NE FINISHED |
Provenance (5 batches)
| Stage | Batch ID | Job type | Status |
|---|---|---|---|
| creating | batch_69ca848940cc8190b97cec654cb3bb4a |
elicitation | completed |
| NER | batch_69cd9b2783b48190a9929dc3e3cd2956 |
ner | completed |
| NED1 | batch_69d18232e34c8190a19685ee9210e88b |
ned_source_triple | completed |
| NED2 | batch_69d1856b88908190a787765e1d8f001f |
ned_description | completed |
| NEDg | batch_69d18324756c819089eb7edc107ed8b2 |
nedg | completed |
Created at: March 30, 2026, 8:11 p.m.